<DOC>
	<DOCNO>NCT01231971</DOCNO>
	<brief_summary>The purpose study build upon information obtain original Alzheimer 's Disease Neuroimaging Initiative ( ADNI1 ) ADNI-GO ( Grand Opportunity ; study fund NIH grant American Recovery Reinvestment Act ) , examine brain image technology use test measure progression mild cognitive impairment ( MCI ) early Alzheimer 's disease ( AD ) . ADNI2 seek inform neuroscience AD . This information aid early detection AD , measure effectiveness treatment future clinical trial .</brief_summary>
	<brief_title>Alzheimer 's Disease Neuroimaging Initiative 2</brief_title>
	<detailed_description>The Alzheimer 's Disease Neuroimaging Initiative ( ADNI ) begin October 2004 landmark study public-private partnership gather analyzed thousand brain scan , genetic profile biomarkers blood cerebrospinal fluid ( CSF ) . Although original goal define biomarkers use clinical trial determine best way measure treatment effect Alzheimer 's disease ( AD ) , goal expand use biomarkers identify AD pre-dementia stage . ADNI1 involve scientist 59 research center , 54 U.S. five Canada . Originally 800 participant enrol . This group comprise 200 participant AD , 400 mild cognitive impairment ( MCI ) 200 normal cognition . In ADNI-GO , estimate 200 participant early amnestic MCI ( EMCI ) enrol understand characterize mild symptomatic phase AD . An additional 650 participant enrol ADNI2 . Some leading-edge technology study brain-imaging technique , positron emission tomography ( PET ) , include FDG-PET ( measure glucose metabolism brain ) ; PET use radioactive compound ( Florbetapir F 18 ) measure brain beta-amyloid ; structural MRI . Brain scan show scientist brain 's structure function change AD start progress . Biomarkers cerebrospinal fluid revealing change could identify patient MCI develop Alzheimer 's . Scientists look level beta-amyloid tau cerebrospinal fluid . ( Abnormal amount amyloid tau protein brain hallmarks Alzheimer 's disease . ) ADNI2 extend work ADNI1 ADNI GO understand progression AD . The overall goal determine relationship among clinical , cognitive , image , genetic biochemical biomarker characteristic entire spectrum AD , pathology evolves normal age mild symptom , MCI , dementia . The overall impact study increase knowledge concern sequence timing event lead MCI AD , development well clinical imaging/fluid biomarker method early detection monitor progression condition , facilitation clinical trial slow disease progression , ultimately contribute prevention AD .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Participants classify either normal control , SMC , EMCI , LMCI AD participant . General Inclusion Criteria apply group , specific criterion group describe : General ( applies category ) : Geriatric Depression Scale le 6 . Age *5590 ( inclusive ) . *For normal control SMC participant , age must 6590 . Study partner available frequent contact participant ( e.g . average 10 hour per week ) , accompany participant clinic visit duration protocol . Visual auditory acuity adequate neuropsychological testing . Good general health disease expect interfere study . Participant pregnant , lactating , childbearing potential ( i.e . woman must two year postmenopausal surgically sterile ) . Willing able participate longitudinal imaging study . Hachinski le equal 4 . Completed six grade education good work history ( sufficient exclude mental retardation ) . Must speak English Spanish fluently . Willing undergo repeat MRIs ( 3Tesla ) least two PET scan ( one FDG one Amyloid imaging ) medical contraindication MRI . Agrees collection blood Genome Wide Association Studies ( GWAS ) , APOE test DNA RNA banking . Agrees collection blood biomarker test . Agrees least one lumbar puncture collection CSF . Specific Inclusion Criteria normal control : Participant must free memory complaint , verify study partner . Normal memory function score Wechsler Memory Scale ( adjust education ) MiniMental State Exam ( MMSE ) score 24 30 ( inclusive ) Clinical Dementia Rating ( CDR ) = 0 ; Memory Box score must 0 Cognitively normal , base absence significant impairment cognitive function activity daily live Stability Permitted Medications 4 week . In particular , participant may take : Antidepressants lack significant anticholinergic side effect Estrogen replacement therapy permissible Gingko biloba permissible , discourage Washout psychoactive medication ( e.g. , excluded antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic , etc . ) least 4 week prior screen Specific Inclusion Criteria SMC participant : Subjects `` selfreferrals '' significant subjective memory concern Significant memory concern confirm Cognitive Change Index score equal 16 Normal memory function score Wechsler Memory Scale ( adjust education ) MiniMental State Exam ( MMSE ) score 24 30 ( inclusive ) Clinical Dementia Rating ( CDR ) = 0 ; Memory Box score must 0 Cognitively normal , base absence significant memory impairment cognitive function activity daily live Stability Permitted Medications 4 week . In particular , subject may take : Antidepressants lack significant anticholinergic side effect Estrogen replacement therapy permissible Gingko biloba permissible , discourage Washout psychoactive medication ( e.g. , excluded antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic , etc . ) least 4 week prior screen Specific Inclusion Criteria EMCI LMCI participant : Participant must subjective memory concern report participant , study partner , clinician Abnormal memory function score Wechsler Memory Scale ( adjust education ) MiniMental State Exam ( MMSE ) score 24 30 ( inclusive ) Clinical Dementia Rating ( CDR ) = 0.5 ; Memory Box score must least 0.5 General cognition functional performance sufficiently preserve diagnosis AD make site physician time screen visit Stability Permitted Medications 4 week . In particular , participant may take : Antidepressants lack significant anticholinergic side effect Estrogen replacement therapy Gingko biloba permissible , discourage Washout psychoactive medication ( e.g. , excluded antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic , etc . ) least 4 week prior screen Cholinesterase inhibitor memantine allowable stable 12 week prior screen Specific Inclusion Criteria AD participant : Participant must subjective memory concern report participant , study partner , clinician Abnormal memory function score Wechsler Memory Scale ( adjust education ) MiniMental State Exam ( MMSE ) score 20 26 ( inclusive ) Clinical Dementia Rating ( CDR ) = 0.5 1.0 National Institute Neurological Communicative Diseases Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable AD Stability Permitted Medications 4 week . In particular , participant may take : Antidepressants lack significant anticholinergic side effect Estrogen replacement therapy Gingko biloba permissible , discourage Washout psychoactive medication ( e.g. , excluded antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic , etc . ) least 4 week prior screen Cholinesterase inhibitor memantine allowable stable 12 week prior screen Specific Inclusion Criteria followup participant ADNI1 ADNI GO : Must enrol follow ADNI1 least one year enrol ADNIGO original diagnosis Cognitively Normal ( CN ) , Mild Cognitive Impairment ( MCI ) , Early Mild Cognitive Impairment ( EMCI ) regardless whether diagnostic conversion occur since initial enrollment ADNI . Willing able continue participate ongoing longitudinal study . A reduced battery test allowable participant able/willing complete full battery . Study partner available frequent contact participant ( e.g . average 10 hour per week ) , accompany participant clinic visit duration protocol . General ( applies category ) : Screening/baseline MRI scan evidence infection , infarction , focal lesion ; Participants multiple lacunes lacunes critical memory structure exclude Presence pacemaker , aneurysm clip , artificial heart valve , ear implant , metal fragment foreign object eye , skin body Major depression , bipolar disorder describe Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) within past 1 year Currently treat medication obsessivecompulsive disorder attention deficit disorder History schizophrenia History alcohol substance abuse dependence within past 2 year Any significant systemic illness unstable medical condition could lead difficulty comply protocol Clinically significant abnormality B12 , TFTs might interfere study Residence skilled nursing facility Current use specific psychoactive medication ( e.g. , certain antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic , etc . ) ; Current use warfarin dabigatran ( exclusionary lumbar puncture ) . Use investigational agent one month prior entry duration trial Participation clinical study involve neuropsychological measure collect one time per year Exclusion FDG PET scan amyloid image Florbetapir F 18 : Current recent participation procedure involve radioactive agent total radiation dose exposure participant give year would exceed limit annual total dose commitment set forth US Code Federal Regulations ( CFR ) Title 21 Section 361.1 . Exceptions guideline may consider casebycase basis discretion protocol director Specific Exclusion Criteria normal control SMC participant : Any significant neurologic disease , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic default know structural brain abnormality Specific Exclusion Criteria EMCI LMCI participant : Any significant neurologic disease suspect incipient Alzheimer 's disease , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic default know structural brain abnormality . Specific Exclusion Criteria AD participant : Any significant neurologic disease Alzheimer 's disease , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic default know structural brain abnormality . Specific Exclusion Criteria followup participant ADNI1 ADNI GO : Participants able participate FDG PET scan amyloid image Florbetapir F 18 follow true : Current recent participation procedure involve radioactive agent total radiation dose exposure participant give year would exceed limit annual total dose commitment set forth US Code Federal Regulations ( CFR ) Title 21 Section 361.1 .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>amyloid</keyword>
	<keyword>plaque</keyword>
	<keyword>neuroimaging</keyword>
	<keyword>biomarkers</keyword>
	<keyword>cognition disorder</keyword>
	<keyword>early detection</keyword>
	<keyword>Amnestic MCI</keyword>
	<keyword>pre-dementia</keyword>
	<keyword>dementia</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>tau</keyword>
</DOC>